David Castro-Diaz ICS Chair
Magnus Fall ICS Chair
#179 12 month patient reported outcomes of a fully-implanted, nickel sized and shaped tibial nerve stimulator for the treatment of overactive bladder syndrome with urgency urinary incontinence PRIZE AWARD: Best in Category Prize - Overactive Bladder
English S1, Lucente V2, Kaaki B3, Gilling P4, Meffan P5, Clark M6, Sand P7, Sen S8, Rovner E9, MacDiarmid S101.Canterbury Urology Research Trust, Christchurch, New Zealand, 2.Institute for Female Pelvic Medicine & Reconstructive Surgery, Allentown, Pennsylvania, USA, 3.Unity Point Health, Waterloo, Iowa, USA, 4.Tauranga Urology Research Ltd, Tauranga, New Zealand, 5.Roundhay Medical Centre, Nelson, New Zealand, 6.The Clark Center for Urogynecology, Newport Beach, California, USA, 7.Northshore University Health System, Skokie, Illinois, USA, 8.Stanford University, Stanford, California, USA, 9.Medical University of South Carolina, Charleston, South Carolina, 10.Alliance Urology Specialists, Greensboro, North Carolina, USA Clinical Trial, Overactive Bladder, Urgency Urinary Incontinence, Quality of Life (QoL), New Devices
#180 Efficacy of vibegron, a novel selective β3-adrenoreceptor agonist, on urgency urinary incontinence with overactive bladder: Post-hoc analysis of phase III study
Yoshida M1, Takeda M2, Gotoh M3, Yokoyama O4, Kakizaki H5, Takahashi S6, Masumori N7, Nagai S8, Hashimoto K8, Minemura K81.Department of Urology, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan, 2.Department of Urology, Graduate School of Medical Sciences, University of Yamanashi, Kofu, Yamanashi, Japan, 3.Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, 4.Department of Urology, Faculty of Medical Science, University of Fukui, Fukui, Japan, 5.Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan, 6.Department of Urology, Nihon University School of Medicine, Tokyo, Japan, 7.Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan, 8.Kyorin Pharmaceutical Co., LTD, Tokyo, Japan Overactive Bladder, Urgency Urinary Incontinence, Urgency/Frequency, Incontinence
#181 Once-Daily Vibegron 75 mg Demonstrates Statistically Significant Benefits on Key Secondary Endpoints Including Quality of Life in Patients With OAB: Data From an International Phase 3 Trial (EMPOWUR)
Staskin D1, Varano S2, Frankel J3, Shortino D4, Jankowich R4, Mudd Jr P41.Tufts University School of Medicine, Boston, MA, 2.Clinical Research Consulting, Milford, CT, 3.Seattle Urology Research Center, Seattle, WA, 4.Urovant Sciences, Inc., Irvine, CA Urgency Urinary Incontinence, Urgency/Frequency, Overactive Bladder
#182 12 YEAR SINGLE CENTER RETROSPECTIVE REVIEW OF RATE AND RISK FACTORS OF TINED LEAD BREAKAGE DURING SACRAL NEUROMODULATION LEAD EXPLANT
Rueb J1, Pizarro-Berdichevsky J2, Derisaviford S1, Goldman H11.Cleveland Clinic, 2.Hospital Dr. Sotero del Rio, Department of Obstetricia y Ginecologia, Pontificia Universidad Catolica de Chile, Santiago, Chile Retrospective Study, Neuromodulation, Surgery
#183 Response and cognitive safety of fesoterodine in patients >65y old with OAB. Is there a relationship between cognition and treatment response?
Wagg A1, Elsobky M2, Carlsson M3, Fernet M21.University of Alberta, 2.Pfizer Canada, 3.Pfizer Corp Overactive Bladder, Gerontology, Retrospective Study
#184 Double blind, placebo-controlled trial of antibiotics in women with refractory Detrusor Overactivity: Effect on urge incontinence and quality of life.
Moore K1, Mansfield K2, Chen Z1, Allen W1, Parkin K1, Gebski V31.Department of Urogynaecology, University of New South Wales at St. George Hospital, Kogarah NSW 2217, Australia., 2.Illawara Health and Medical Research Institute, School of Medicine, University of Wollongong, Wollongong NSW 2522, Australia., 3.NHMRC Clincial Trials Centre, University of Sydney, Sydney, NSW 2522, Australia Detrusor Overactivity, Pad Test, Clinical Trial, Infection, Urinary Tract, Urgency Urinary Incontinence
#185 Continuous Intravesical Delivery of Trospium Chloride Significantly Improves OAB Symptoms: Results of a Phase 1b Study
Cutie C1, Efros M2, Sobol J3, Gilleran J4, Maffeo J1, Kennelly M51.TARIS Biomedical LLC, 2.AccuMed Research Associates, 3.Michigan Institute of Urology, 4.William Beaumont Hospital, 5.McKay Urology Clinical Trial, Urgency Urinary Incontinence, Overactive Bladder, Quality of Life (QoL)
#186 Treatment of Overative Bladder with a Peritrigonal Injection Paradigm of OnabotulinumtoxinA is Associated with a Low Incidence of Clean Intermittent Catheterization
MacDiarmid S1, Glazier D2, Shapiro A3, McCrery R4, Jarnagin B5, Boroujerdi A6, Bai Z6, Gao G6, Patel A6, McCammon K71.Alliance Urology Specialists, 2.Virginia Urology, 3.Chesapeake Urology, 4.Adult Pediatric Urology & Urogynecology, PC, 5.Center for Pelvic Health, 6.Allergan plc, 7.Eastern Virginia Medical School Clinical Trial, Incontinence, Overactive Bladder, Neuromodulation, Pharmacology
#187 The OAB Patient's Pathway: Is It a Long and Bumpy Road? A Quantitative Analysis.
Witte L1, Elburg R2, Hollegien L1, Blanker M21.Isala Clinics, Zwolle, the Netherlands, 2.University Medical Center Groningen, the Netherlands Conservative Treatment, Overactive Bladder, Urgency Urinary Incontinence, Urgency/Frequency, Female
#188 Will detrusor overactivity progress to detrusor underactivity? A longitudinal long-term urodynamic follow-up in patients with overactive bladder syndrome
Chen S1, Jiang Y1, Ping-Jui L1, Kuo H11.Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan Nocturia, Detrusor Overactivity, Bladder Outlet Obstruction
#189 Long-term follow-up of intravesical onabotulinum toxin-A injections in male patients with idiopathic OAB: the role of prostate surgery
Bels J1, Marcelissen T2, De Beij J1, De Vries P1, Rademakers K11.Zuyderland MC, 2.Maastricht Universitair Medisch Centrum Overactive Bladder, Benign Prostatic Hyperplasia (BPH), Male, Retrospective Study, Incontinence
#190 MANAGEMENT OF PATIENTS WITH OVERACTIVE BLADDER WHO FAIL INTRADETRUSOR ONABOTULINUMTOXINA INJECTIONS: WHAT HAPPENS NEXT?
Zahner P1, Giusto L1, Derisavifard S1, Rueb J1, Courtenay M1, Rackley R1, Vasavada S1, Goldman H11.Cleveland Clinic Foundation Detrusor Overactivity, Overactive Bladder, Retrospective Study, Urgency Urinary Incontinence, Incontinence